A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) | MicrobiomeTrials
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-04-02Est. Completion: 2031-01-17
Enrollment target: 572 participants
Locations
Stanford Cancer Center, Palo Alto, California, United States
University of California San Francisco, San Francisco, California, United States
University of Miami, Miami, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Indiana University Cancer Center, Indianapolis, Indiana, United States
University of Kansas Hospital Authority, Kansas City, Kansas, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Henry Ford Hospital, Detroit, Michigan, United States
Washington University, St Louis, Missouri, United States
Mount Sinai Hospital, New York, New York, United States
Memorial Sloan Kettering, New York, New York, United States
University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States
Other microbiome trials you might be interested in